$HRGN
Harvard Apparatus Regenerative Technology, Inc. Stock $hrgn

$hrgn Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223009840 Filed on March 30, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.378M	$768.0K	$4.411M
YoY Change	25.03%	-85.65%	-37.38%
% of Gross Profit
Research & Development	$509.0K	$725.0K	$1.742M
YoY Change	67.99%	31.82%	9.42%
% of Gross Profit
Depreciation & Amortization	$12.00K	$12.00K	$52.00K
YoY Change	-14.29%	-40.0%	-51.4%
% of Gross Profit
Operating Expenses	$2.887M	$1.493M	$6.153M
YoY Change	30.93%	-74.7%	-28.75%
Operating Profit	-$2.887M		-$6.153M
YoY Change	30.93%		-28.75%
Interest Expense			$9.000K
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$3.000K	-$2.000K	$80.00K
YoY Change	-110.71%	-107.14%	-87.84%
Pretax Income	-$2.890M	-$1.495M	-$6.073M
YoY Change	32.75%	-74.54%	-23.88%
Income Tax
% Of Pretax Income
Net Earnings	-$2.890M	-$1.580M	-$6.073M
YoY Change	32.75%	-73.1%	-23.88%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.24		-$0.54
Diluted Earnings Per Share	-$0.24	-$0.13	-$0.55
COMMON SHARES
Basic Shares Outstanding	12.21M shares	11.64M	11.35M shares
Diluted Shares Outstanding	12.21M shares		11.35M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.269M	$1.241M	$1.241M
YoY Change	352.14%	-0.08%	-0.08%
Cash & Equivalents	$3.269M	$1.241M
Short-Term Investments
Other Short-Term Assets	$357.0K	$51.00K	$353.0K
YoY Change	-88.87%	325.0%	2.32%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$3.626M	$1.594M	$1.594M
YoY Change	-7.74%	0.44%	0.44%
LONG-TERM ASSETS
Property, Plant & Equipment	$46.00K	$49.00K	$196.0K
YoY Change	-52.08%	-55.45%	-29.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$544.0K	$610.0K	$610.0K
YoY Change
Total Long-Term Assets	$710.0K	$806.0K	$806.0K
YoY Change	198.32%	188.89%	188.89%
TOTAL ASSETS
Total Short-Term Assets	$3.626M	$1.594M	$1.594M
Total Long-Term Assets	$710.0K	$806.0K	$806.0K
Total Assets	$4.336M	$2.400M	$2.400M
YoY Change	4.03%	28.62%	28.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$755.0K	$682.0K	$682.0K
YoY Change	-40.69%	0.89%	0.89%
Accrued Expenses	$563.0K	$669.0K	$669.0K
YoY Change	-86.44%	-83.91%	-83.91%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.326M	$1.363M	$1.363M
YoY Change	-85.44%	-71.82%	-71.82%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$21.00K	$48.00K	$48.00K
YoY Change	-30.0%	-18.64%	-18.64%
Total Long-Term Liabilities	$21.00K	$48.00K	$48.00K
YoY Change	-30.0%	-18.64%	-18.64%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.326M	$1.363M	$1.363M
Total Long-Term Liabilities	$21.00K	$48.00K	$48.00K
Total Liabilities	$1.347M	$1.411M	$1.411M
YoY Change	-85.26%	-71.17%	-71.17%
SHAREHOLDERS EQUITY
Retained Earnings	-$85.90M	-$83.00M
YoY Change	8.6%	7.88%
Common Stock	$127.0K	$122.0K
YoY Change	17.59%	12.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.062M	-$3.191M	$989.0K
YoY Change
Total Liabilities & Shareholders Equity	$4.336M	$2.400M	$2.400M
YoY Change	4.03%	28.62%	28.62%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$2.890M	-$1.580M	-$6.073M
YoY Change	32.75%	-73.1%	-23.88%
Depreciation, Depletion And Amortization	$12.00K	$12.00K	$52.00K
YoY Change	-14.29%	-40.0%	-51.4%
Cash From Operating Activities	-$1.013M	-$1.733M	-$5.106M
YoY Change	95.18%	73.13%	94.29%
INVESTING ACTIVITIES
Capital Expenditures	$9.000K	-$3.000K	$5.000K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$9.000K	$3.000K	-$5.000K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$3.050M	0.000	$5.060M
YoY Change	-0.16%	-100.0%	77.92%
NET CHANGE
Cash From Operating Activities	-$1.013M	-1.733M	-$5.106M
Cash From Investing Activities	-$9.000K	3.000K	-$5.000K
Cash From Financing Activities	$3.050M	0.000	$5.060M
Net Change In Cash	$2.028M	-1.730M	-$51.00K
YoY Change	-20.03%	129.75%	-123.61%
FREE CASH FLOW
Cash From Operating Activities	-$1.013M	-$1.733M	-$5.106M
Capital Expenditures	$9.000K	-$3.000K	$5.000K
Free Cash Flow	-$1.022M	-$1.730M	-$5.111M
YoY Change	96.92%	72.83%	94.48%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001563665
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent		usd
CY2021Q4	BSTG	Prepaid Research And Development Current PrepaidResearchAndDevelopmentCurrent		usd
CY2021Q4	BSTG	Deferred Financing Cost Non Current DeferredFinancingCostNonCurrent		usd
CY2022Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue		usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2021	us-gaap	Sublease Income SubleaseIncome		usd
CY2022	BSTG	Grant Income GrantIncome		usd
CY2021	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment		usd
CY2022	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues		usd
CY2022	BSTG	Issuance Of Common Stock From Exercise Of Warrants IssuanceOfCommonStockFromExerciseOfWarrants		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2021	BSTG	Increase Decrease In Deferred Financing Costs IncreaseDecreaseInDeferredFinancingCosts		usd
CY2022	BSTG	Increase Decrease In Grant Receivables IncreaseDecreaseInGrantReceivables		usd
CY2021	BSTG	Increase Decrease In Prepaid Research And Development IncreaseDecreaseInPrepaidResearchAndDevelopment		usd
CY2022	BSTG	Increase Decrease In Accrual For Contingency Matter IncreaseDecreaseInAccrualForContingencyMatter		usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2021	BSTG	Settlement Of Contingency Matter SettlementOfContingencyMatter		usd
CY2021	BSTG	Settlement Amount Due To Parent Included In Accrued And Other Current Liabilities SettlementAmountDueToParentIncludedInAccruedAndOtherCurrentLiabilities		usd
CY2021	us-gaap	Stock Issued1 StockIssued1		usd
CY2021	us-gaap	Dividends Preferred Stock DividendsPreferredStock		usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent		usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent		usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue		usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits		pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost		pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements		usd
CY2022Q4	BSTG	Deferred Tax Assets Excess Book Over Tax Depreciation DeferredTaxAssetsExcessBookOverTaxDepreciation		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-35853
CY2022	dei	Entity Registrant Name EntityRegistrantName	BIOSTAGE, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-5210462
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	84 October Hill Road, Suite 11
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Holliston
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	01746
CY2022	dei	City Area Code CityAreaCode	(774)
CY2022	dei	Local Phone Number LocalPhoneNumber	233-7300
CY2022	dei	Security12b Title Security12bTitle	None
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	34500000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	12206400	shares
CY2022	dei	Auditor Firm AuditorFirmId	688
CY2021	dei	Auditor Firm AuditorFirmId	2388
CY2022	dei	Auditor Name AuditorName	Marcum LLP
CY2022	dei	Auditor Location AuditorLocation	Boston, MA
CY2021	dei	Auditor Name AuditorName	Wei, Wei & Co., LLP
CY2021	dei	Auditor Location AuditorLocation	Flushing, New York
CY2022Q4	us-gaap	Cash Cash	1241000	usd
CY2021Q4	us-gaap	Cash Cash	1242000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	50000	usd
CY2022Q4	BSTG	Prepaid Research And Development Current PrepaidResearchAndDevelopmentCurrent	274000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	79000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	295000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1594000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	1587000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	49000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	110000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	147000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	169000	usd
CY2022Q4	BSTG	Deferred Financing Cost Non Current DeferredFinancingCostNonCurrent	610000	usd
CY2022Q4	us-gaap	Assets Assets	2400000	usd
CY2021Q4	us-gaap	Assets Assets	1866000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	682000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	676000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	582000	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	798000	usd
CY2021Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	3250000	usd
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	99000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	110000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1363000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4836000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	48000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	59000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1411000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	4895000	usd
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	5000	shares
CY2021Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	5000	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	4180	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	4180	shares
CY2021Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	4180	shares
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	4180	shares
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	4180000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12174467	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12174467	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10760871	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10760871	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	122000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	108000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	79698000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	73801000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-83011000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-76938000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3191000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-3029000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2400000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1866000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1742000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1592000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4411000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7044000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	6153000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	8636000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-6153000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-8636000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	408000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	87000	usd
CY2021	BSTG	Grant Income GrantIncome	165000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2000	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-15000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-9000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	70000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	80000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	658000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-6073000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-7978000	usd
CY2022	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	180000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6253000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7978000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.54
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.79
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11349610	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10062432	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1125000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-7978000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	980000	usd
CY2021	BSTG	Issuance Of Common Stock And Warrants To Purchase Common Stock Value Net Of Offering Costs IssuanceOfCommonStockAndWarrantsToPurchaseCommonStockValueNetOfOfferingCosts	2844000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-3029000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-6073000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1031000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	-180000	usd
CY2022	BSTG	Issuance Of Common Stock And Warrants To Purchase Common Stock Value Net Of Offering Costs IssuanceOfCommonStockAndWarrantsToPurchaseCommonStockValueNetOfOfferingCosts	5060000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3191000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-6073000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-7978000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	408000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1031000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	980000	usd
CY2022	us-gaap	Depreciation Depreciation	52000	usd
CY2021	us-gaap	Depreciation Depreciation	107000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2000	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-15000	usd
CY2022	BSTG	Increase Decrease In Deferred Financing Costs IncreaseDecreaseInDeferredFinancingCosts	610000	usd
CY2021	BSTG	Increase Decrease In Grant Receivables IncreaseDecreaseInGrantReceivables	-77000	usd
CY2022	BSTG	Increase Decrease In Prepaid Research And Development IncreaseDecreaseInPrepaidResearchAndDevelopment	274000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-216000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-229000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	645000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	548000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	485000	usd
CY2021	BSTG	Increase Decrease In Accrual For Contingency Matter IncreaseDecreaseInAccrualForContingencyMatter	3250000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5106000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2628000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5000	usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	5060000	usd
CY2021	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	2844000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5060000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2844000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-51000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	216000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1292000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1076000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1241000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1292000	usd
CY2022	BSTG	Settlement Of Contingency Matter SettlementOfContingencyMatter	-3250000	usd
CY2022	BSTG	Settlement Amount Due To Parent Included In Accrued And Other Current Liabilities SettlementAmountDueToParentIncludedInAccruedAndOtherCurrentLiabilities	-750000	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	4000000	usd
CY2022	us-gaap	Dividends Preferred Stock DividendsPreferredStock	180000	usd
CY2022	BSTG	Increase Of Right Of Use Asset And Liability Due To Lease Extension IncreaseOfRightOfUseAssetAndLiabilityDueToLeaseExtension	63000	usd
CY2021	BSTG	Increase Of Right Of Use Asset And Liability Due To Lease Extension IncreaseOfRightOfUseAssetAndLiabilityDueToLeaseExtension	94000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-83000000.0	usd
CY2022Q4	us-gaap	Cash Cash	1200000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	79000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84F_eus-gaap--UseOfEstimates_zFjIyT6nCX8i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_z37OIDDqFf5a">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The process of preparing consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Such estimates include, but are not limited to, share-based compensation, valuation of warrant liability, accrued expenses and the valuation allowance for deferred income taxes. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q4	us-gaap	Cash Cash	1241000	usd
CY2021Q4	us-gaap	Cash Cash	1242000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	50000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1241000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1292000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	50000	usd
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_z2ypqyONLUv6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zfWe70wLZr9c">Concentration of Credit Risk</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial investments that potentially subject the Company to credit risk consist of cash. The Company has all cash at accredited financial institutions. Bank accounts in the United States are insured by the Federal Deposit Insurance Corporation (FDIC) up to $<span id="xdx_904_eus-gaap--CashFDICInsuredAmount_iI_c20221231_z8DZeidmNJdc" title="Cash insured by FDIC">250,000</span>. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2018Q1	BSTG	Maximum Research And Development Expenses Reimbursement MaximumResearchAndDevelopmentExpensesReimbursement	200000	usd
CY2022Q4	us-gaap	Grants Receivable GrantsReceivable	1800000	usd
CY2022	BSTG	Grants Receivable Recognized GrantsReceivableRecognized	1500000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	12000	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	50000	usd
CY2021Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	2000	usd
CY2022	BSTG	Fair Value Transfers Between Level Hierarchies FairValueTransfersBetweenLevelHierarchies	0	usd
CY2021	BSTG	Fair Value Transfers Between Level Hierarchies FairValueTransfersBetweenLevelHierarchies	0	usd
CY2022Q4	BSTG	Prepaid Deposits PrepaidDeposits	20000	usd
CY2021Q4	BSTG	Prepaid Deposits PrepaidDeposits	225000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	8000	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	58000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	51000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	55000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	12000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	582000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	798000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	295000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1476000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2614000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1427000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2504000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	49000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	110000	usd
CY2022Q4	BSTG	Property Plant And Equipment Wrote Off PropertyPlantAndEquipmentWroteOff	1100000	usd
CY2022	us-gaap	Depreciation Depreciation	52000	usd
CY2021	us-gaap	Depreciation Depreciation	107000	usd
CY2022Q4	BSTG	Accrued Legal Expenses Current AccruedLegalExpensesCurrent	135000	usd
CY2021Q4	BSTG	Accrued Legal Expenses Current AccruedLegalExpensesCurrent	577000	usd
CY2022Q4	BSTG	Accrued Advisory Costs Current AccruedAdvisoryCostsCurrent	300000	usd
CY2021Q4	BSTG	Accrued Advisory Costs Current AccruedAdvisoryCostsCurrent	151000	usd
CY2022Q4	BSTG	Accrued Audit Services Current AccruedAuditServicesCurrent	80000	usd
CY2021Q4	BSTG	Accrued Audit Services Current AccruedAuditServicesCurrent	59000	usd
CY2017Q4	BSTG	Warrants To Be Remeasured Number WarrantsToBeRemeasuredNumber	1044396	shares
CY2017Q4	BSTG	Warrants To Be Modified Number WarrantsToBeModifiedNumber	952184	shares
CY2022Q4	BSTG	Warrants To Be Remeasured Number WarrantsToBeRemeasuredNumber	92212	shares
CY2022Q1	BSTG	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Expired SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExpired	92212	shares
CY2021	BSTG	Fair Value Assumption Risk Free Interest Rate FairValueAssumptionRiskFreeInterestRate	0.0005	pure
CY2021	BSTG	Fair Value Assumptions Expected Volatility Rates FairValueAssumptionsExpectedVolatilityRates	174.54	pure
CY2021	BSTG	Fair Value Assumptions Expected Terms FairValueAssumptionsExpectedTerms	P0Y1M6D
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	8.00
CY2021Q4	us-gaap	Share Price SharePrice	2.30
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	17000	usd
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	15000	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	2000	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	2000	usd
CY2017Q2	BSTG	Number Of Synthetic Trachea Scaffold Product NumberOfSyntheticTracheaScaffoldProduct	1	item
CY2017Q2	BSTG	Number Of Bioreactors NumberOfBioreactors	2	item
CY2021	BSTG	Increase Decrease In Accrual For Contingency Matter IncreaseDecreaseInAccrualForContingencyMatter	3300000	usd
CY2022Q4	us-gaap	Loss Contingency Estimate Of Possible Loss LossContingencyEstimateOfPossibleLoss	5900000	usd
CY2022Q4	BSTG	Percentage Of Litigation Paid PercentageOfLitigationPaid	1	pure
CY2022Q4	BSTG	Loss Contingency Accrual At Cost LossContingencyAccrualAtCost	3300000	usd
CY2022	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	2600000	usd
CY2022Q4	us-gaap	Loss Contingency Estimate Of Possible Loss LossContingencyEstimateOfPossibleLoss	5900000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	147000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	169000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	99000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	110000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	48000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	59000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	147000	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	169000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	121000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	121000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y5M4D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y7M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1474	pure
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0914	pure
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	121000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	121000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	20274000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	40000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	114000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	50000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	164000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	17000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	147000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.063	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.063	pure
CY2022	BSTG	Effective Income Tax Rate Reconciliation Nondeductible Expense Change In Fair Value Of Warrants And Share Based Payment Arrangement Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantsAndShareBasedPaymentArrangementPercent	0.008	pure
CY2021	BSTG	Effective Income Tax Rate Reconciliation Nondeductible Expense Change In Fair Value Of Warrants And Share Based Payment Arrangement Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantsAndShareBasedPaymentArrangementPercent	0.010	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.021	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.002	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.281	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.260	pure
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	20487000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	16611000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1083000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1470000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1566000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1284000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements	888000	usd
CY2022Q4	BSTG	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	40000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	46000	usd
CY2022Q4	BSTG	Deferred Tax Liability Operating Lease Assets DeferredTaxLiabilityOperatingLeaseAssets	-40000	usd
CY2021Q4	BSTG	Deferred Tax Liability Operating Lease Assets DeferredTaxLiabilityOperatingLeaseAssets	-46000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	40000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	46000	usd
CY2021Q4	BSTG	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	46000	usd
CY2021Q4	BSTG	Deferred Tax Assets Excess Book Over Tax Depreciation DeferredTaxAssetsExcessBookOverTaxDepreciation	21000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	23176000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	20320000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	23136000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2900000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2100000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	35000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	39000	usd
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	44194987	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1893201	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.44
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	686232	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.08
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	78014	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	35.20
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2501419	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.35
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	427390	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.88
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	775000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	7.17
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	1040187	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	7.59
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1113622	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.69
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3630546	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.23
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.84
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-6073000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-7978000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11349610	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10062432	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.54
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.79
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4834022	shares

Files In Submission

Name	View Source	Status
0001493152-23-009840-index-headers.html	Edgar Link	pending
0001493152-23-009840-index.html	Edgar Link	pending
0001493152-23-009840.txt	Edgar Link	pending
0001493152-23-009840-xbrl.zip	Edgar Link	pending
bstg-20221231.xsd	Edgar Link	pending
bstg-20221231_cal.xml	Edgar Link	unprocessable
chart_1.jpg	Edgar Link	pending
chart_2.jpg	Edgar Link	pending
chart_3.jpg	Edgar Link	pending
chart_4.jpg	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex23-2.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
bstg-20221231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
bstg-20221231_def.xml	Edgar Link	unprocessable
bstg-20221231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HRGN
Harvard Apparatus Regenerative Technology, Inc. Stock $hrgn

2023 Q1 Form 10-K Financial Statement

#000149315223009840 Filed on March 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HRGN Harvard Apparatus Regenerative Technology, Inc. Stock $hrgn

2023 Q1 Form 10-K Financial Statement

#000149315223009840 Filed on March 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HRGN
Harvard Apparatus Regenerative Technology, Inc. Stock $hrgn